Cytotoxic Chemotherapy Pharmacology: Drug Classes, DPYD Testing and Safety

Evidence and references reviewed 10 November 2026.

Cytotoxic chemotherapy damages DNA, limits nucleotide synthesis or interferes with cell division. Its effects on healthy proliferating tissues help explain marrow suppression, mucositis and hair loss. The goal may be cure, reduction of recurrence risk, disease control or relief of symptoms. That goal influences the acceptable toxicity of a regimen.1

Why cytotoxic chemotherapy affects normal tissues

Many cytotoxic medicines injure cells by interfering with DNA synthesis or integrity, mitotic spindle function, nucleotide production or DNA damage responses. Rapidly proliferating normal tissues are vulnerable: bone marrow (neutropenia, anemia, thrombocytopenia), gastrointestinal mucosa (mucositis and diarrhea) and hair follicles (alopecia). Other organ toxicities, such as cisplatin-associated nephrotoxicity or anthracycline-related cardiomyopathy, are not explained by proliferation rate alone.1,2,5

Pharmacologic group Example Mechanism Clinically important toxicity
Platinum coordination complexes Cisplatin, carboplatin DNA adducts and cross-links that impair replication and transcription. Renal, neural, auditory and myelosuppressive effects differ between products.
Alkylating agents Cyclophosphamide Activated metabolite forms DNA cross-links. Myelosuppression and hemorrhagic cystitis from acrolein exposure.
Antifolates Methotrexate Inhibits dihydrofolate reductase and interferes with nucleotide synthesis. Mucositis, cytopenias, renal toxicity; leucovorin rescue in selected high-dose regimens.
Pyrimidine analogues 5-FU, capecitabine, cytarabine Disrupt thymidylate synthesis or DNA synthesis by agent-specific pathways. GI and marrow toxicity; DPD deficiency is critical for 5-FU/capecitabine.
Topoisomerase II inhibitors Doxorubicin, etoposide Interfere with DNA repair and strand rejoining; doxorubicin also intercalates DNA. Cardiomyopathy (anthracyclines), marrow injury, secondary malignancy risk.
Microtubule agents Vincristine, paclitaxel Vinca agents impair polymerization; taxanes stabilize microtubules. Neuropathy and vesicant injury; vincristine is never intrathecal.

Cell-cycle specificity varies. Antimetabolites are generally most active during S phase; microtubule agents primarily disrupt mitosis. Nevertheless, dosing and schedules also depend on drug exposure, repair capacity, tumor biology, marrow reserve and combination regimen evidence. Cytotoxic drugs are not interchangeable simply because two agents affect DNA.

How representative drugs act

Platinum compounds. Cisplatin forms DNA cross-links that interfere with replication. Kidney injury, hearing damage, neuropathy and severe emesis are important risks. Hydration and antiemetic prophylaxis are part of administration. Renal function and electrolytes require assessment over successive cycles.2

Antimetabolites. Methotrexate inhibits dihydrofolate reductase and limits synthesis of purines and thymidylate. Cytarabine is a pyrimidine analogue of cytidine. Cells convert it to an active triphosphate that interferes with DNA synthesis during S phase. These drugs share a broad class but have different activation pathways and dosing regimens.3,4

Anthracyclines. Doxorubicin intercalates into DNA and interferes with topoisomerase II. Cumulative exposure increases cardiomyopathy risk, so previous anthracycline treatment matters when planning a new course. Leakage into surrounding tissue can cause necrosis and requires immediate management under the extravasation protocol.5

Vinca alkaloids. Vincristine interferes with the mitotic spindle. The route is a critical safety issue. Vincristine injection must be administered intravenously, and intrathecal administration is usually fatal. The manufacturer directs dilution in a flexible plastic container with prominent intravenous-only labelling.6,7

Pharmacokinetics, exposure and rescue medicines

Some cytotoxic medicines have a relatively short plasma elimination half-life but persistent biological effects from DNA adducts or intracellular active metabolites. Renal and hepatic function, body size, cumulative exposure and interacting medicines can markedly change toxicity. Specialized dosing, infusion time and rescue protocols are part of the pharmacology—not administrative details.

High-dose methotrexate requires careful hydration, urine alkalinization, serial methotrexate concentrations and leucovorin rescue according to a protocol; glucarpidase may be indicated for severe delayed clearance with kidney injury under specific criteria. Leucovorin rescue should not be confused with routine folic-acid supplementation or automatically applied to every low-dose methotrexate prescription.3

Cisplatin administration includes a plan for hydration, kidney function, magnesium and potassium, hearing symptoms, nausea prevention and cumulative neuropathy. Doxorubicin requires attention to cumulative anthracycline dose, cardiac function, prior chest radiation and other cardiotoxic drugs.2,5

Why treatment is organized into cycles

A cycle combines a defined treatment period with time for recovery. Agents can be combined to attack malignant cells by different mechanisms. The regimen specifies which drugs to give, their order, route and day of administration. For example, gemcitabine and cisplatin are used together in several cancers, including bladder and biliary tract cancers. Treatment schedules depend on the disease and regimen.1,8

Drug-specific monitoring and emergency precautions

Regimen issue What clinicians monitor Why it matters
Myelosuppression Blood count, fever, bleeding, treatment nadir and clinical status. Febrile neutropenia can cause rapid sepsis.
GI injury Oral mucositis, intake, diarrhea, fluids, electrolytes. Dehydration, infection and treatment interruptions may result.
Extravasation Infusion site pain, swelling, erythema or leakage. Vesicant medicines such as vincristine or doxorubicin can cause tissue necrosis.
Renal and auditory injury Creatinine, electrolytes, tinnitus and hearing. Important with cisplatin and some combination regimens.
Cardiac injury Symptoms and ejection fraction when indicated. Potential anthracycline dysfunction, sometimes delayed.
Neuropathy Distal sensation, pain, walking and functional difficulties. Vinca, taxane and platinum medicines may require dose modification.

Vincristine administration safety is nonnegotiable: it must be given intravenously only, with specific container and pharmacy safeguards; accidental intrathecal administration is usually fatal. Suspected vesicant extravasation must be managed immediately through the institutional antidote and line-management protocol rather than home heating or massage instructions.6,7

Fluorouracil and DPD deficiency

Dihydropyrimidine dehydrogenase (DPD) is important for fluorouracil breakdown. Markedly reduced activity can produce early, severe toxicity. US fluorouracil injection labelling directs testing for DPYD variants before treatment unless immediate treatment is necessary. It advises avoiding use in patients with variants that cause complete DPD deficiency. The result must be interpreted alongside clinical findings, including early mucositis, diarrhoea and neutropenia.9

2026 FDA label update: test DPYD before fluoropyrimidine chemotherapy

Dihydropyrimidine dehydrogenase (DPD), encoded by DPYD, catabolizes most administered fluorouracil (5-FU). Some inherited reduced-function variants cause partial or complete DPD deficiency, raising the risk of early severe or fatal mucositis, diarrhea, neutropenia and neurotoxicity. Capecitabine is a prodrug that becomes 5-FU and has analogous risks.9,11

In a 2026 FDA safety communication, updated boxed warnings for both drugs advise testing for relevant DPYD genetic variants before starting treatment unless immediate therapy is necessary. Patients with variants causing complete or near-complete DPD deficiency should generally avoid these fluoropyrimidines; partial deficiency requires specialist individualized selection and dosing. A negative variant test does not exclude every possible DPD defect or make an individual immune to toxicity. Genetic testing informs safer prescribing but does not replace clinical assessment and monitoring.11

Patients with abrupt severe diarrhea, extensive mouth sores, fever, confusion or collapse early in 5-FU/capecitabine treatment require urgent oncologic evaluation. Uridine triacetate is an approved emergency antidote for selected early-onset severe/life-threatening toxicity or overdose, with time-sensitive initiation according to its label; do not wait for every test result when toxicity is life threatening.12

What requires immediate attention

Fever or chills during chemotherapy can signal a serious infection, particularly when neutrophils are low. Patients need an oncology contact and instructions for urgent assessment. The National Cancer Institute advises contacting the treatment team before taking fever-reducing medicines because they can mask signs of infection. Monitoring between cycles should also address cumulative toxicities such as hearing changes with cisplatin or cardiac dysfunction with doxorubicin.10,2,5

Fever during chemotherapy is an emergency until assessed

Neutropenia reduces the ability to mount a normal inflammatory response, so serious infection may initially show fever alone without obvious localizing signs. Patients receiving myelosuppressive chemotherapy should be told to contact their oncology team urgently for a temperature of 38.0°C (100.4°F) or more or as required by the treating center. Some protocols use additional criteria for sustained temperature or absolute neutrophil count. Do not self-manage fever with leftover antibiotics or mask it with antipyretics before contacting the team.10

Antiemetic prophylaxis should be selected by the regimen’s emetic risk, with 5-HT3 antagonists, NK1 antagonists, corticosteroids or olanzapine used as appropriate. For antiemetic mechanisms and interactions, see our antiemetics pharmacology guide.

Frequently asked questions

Are all cancer chemotherapy drugs cell-cycle-specific?

No. Different classes have different cell-cycle associations and cumulative effects.

Can the same chemotherapy dose be used regardless of kidney function?

No. Organ function and regimen-specific pharmacokinetics can require adjustment, delay or a different medicine.

Is DPYD testing advised before capecitabine or 5-FU?

Yes under updated 2026 FDA labels, unless immediate treatment is necessary. Specialists interpret genotype and clinical context.11

Why is intrathecal vincristine dangerous?

It causes severe neurological injury and is usually fatal; administration must be intravenous only.7

Does leucovorin rescue make high-dose methotrexate completely safe?

No. Rescue must be timely and monitored, and renal dysfunction or delayed elimination can cause serious toxicity.

References

  1. National Cancer Institute. Chemotherapy and you [Internet]. [cited 2026 Nov 10]. Available from: https://www.cancer.gov/publications/patient-education/chemotherapy-and-you.pdf
  2. National Library of Medicine. Cisplatin injection prescribing information. DailyMed [Internet]. [cited 2026 Nov 10]. Available from: https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=508496cb-3441-46b3-a4fe-e0d440e6adc6
  3. National Cancer Institute. Methotrexate. NCI Drug Dictionary [Internet]. [cited 2026 Nov 10]. Available from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/methotrexate
  4. National Cancer Institute. Cytarabine. NCI Drug Dictionary [Internet]. [cited 2026 Nov 10]. Available from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/cytarabine
  5. US Food and Drug Administration. Doxorubicin hydrochloride injection prescribing information [Internet]. [cited 2026 Nov 10]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/050629s029lbl.pdf
  6. National Cancer Institute. Vincristine sulfate. NCI Drug Dictionary [Internet]. [cited 2026 Nov 10]. Available from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/vincristine-sulfate
  7. Pfizer. Vincristine sulfate injection prescribing information. Warnings [Internet]. [cited 2026 Nov 10]. Available from: https://www.pfizermedical.com/vincristine/warnings
  8. National Cancer Institute. Gemcitabine–cisplatin [Internet]. [cited 2026 Nov 10]. Available from: https://www.cancer.gov/about-cancer/treatment/drugs/gemcitabine-cisplatin
  9. US Food and Drug Administration. Fluorouracil injection prescribing information [Internet]. [cited 2026 Nov 10]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/216494Orig1s005lbl.pdf
  10. National Cancer Institute. Infection and neutropenia during cancer treatment [Internet]. [cited 2026 Nov 10]. Available from: https://www.cancer.gov/about-cancer/treatment/side-effects/infection
  11. US Food and Drug Administration. Safety labeling update for capecitabine and fluorouracil (5-FU) on risks associated with DPD deficiency [Internet]. 2026. Available from: FDA communication [cited 2026 Nov 10].
  12. National Cancer Institute. Uridine triacetate [Internet]. Available from: NCI Drug Dictionary [cited 2026 Nov 10].

⚠️ Medical Disclaimer

This article is intended for educational and informational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this article.

The information provided here is based on current scientific literature and established pharmacological principles. However, medical knowledge evolves continuously, and individual patient responses to medications may vary. Healthcare professionals should always use their clinical judgment when applying this information to patient care.

Medical & AI Disclaimer

The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.

We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.

Leave a Reply

Your email address will not be published. Required fields are marked *